ImmuneOncia Therapeutics, Inc.
ImmuneOncia Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in South Korea (KR), is at the forefront of developing innovative immunotherapies for cancer treatment. Founded in 2015, the company has rapidly established itself within the biotechnology industry, focusing on the discovery and development of novel therapeutic agents that harness the body's immune system to combat malignancies. ImmuneOncia's core offerings include cutting-edge monoclonal antibodies and immune-modulating therapies, distinguished by their unique mechanisms of action and potential to improve patient outcomes. With a strong emphasis on research and development, the company has achieved significant milestones, including successful clinical trials that underscore its commitment to advancing cancer care. As a leader in the immuno-oncology sector, ImmuneOncia Therapeutics continues to make strides in transforming the landscape of cancer treatment.
DitchCarbon Score
How does ImmuneOncia Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ImmuneOncia Therapeutics, Inc.'s score of 0 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ImmuneOncia Therapeutics, Inc., headquartered in South Korea (KR), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. As there are no emissions data or reduction initiatives available, it is unclear how ImmuneOncia Therapeutics aligns with industry standards for climate action. The absence of emissions reporting may reflect a broader trend within the biotechnology sector, where companies are increasingly being urged to disclose their environmental impact and set ambitious targets for carbon reduction. In summary, without available emissions data or climate commitments, ImmuneOncia Therapeutics, Inc. appears to have no current initiatives in place to address carbon emissions or contribute to climate action efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 7,492,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 15,246,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ImmuneOncia Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
